[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alk-sensitizing-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alk-sensitizing-mutation":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100534111",false,"NCT06234579","Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)","\"GALILEO (Genomic ALteratIons and cLonal EvOlution in ALK+ NSCLC) - Valutazione Longitudinale Delle Alterazioni Genomiche e Clonali Nei Pazienti Affetti da Neoplasie Polmonari ALK-riarrangiate\".","GALILEO","Inclusion Criteria:\n\n* a) histologically confirmed diagnosis of advanced NSCLC with ALK rearrangement detection by NGS (ALK+ NSCLCs patients detected at diagnosis by in hybridization (FISH), immunohistochememistry (IHC), or reverse transcriptase-PCR (RT-PCR) can be included if adequate tissue for NGS is available)\n\n  b) to have received upfront treatment with alectinib, brigatinib or lorlatinib for at least 28 days\n\n  c) ECOG PS 0-2\n\n  d) adult patients (aged ≥ 18 years) at the moment of diagnosis\n\n  e) signing of informed consent approved by the local Ethic Committee\n\nExclusion Criteria:\n\na) Diagnosis of lung cancer without ALK rearrangement\n\na) early withdrawn of treatment due to toxicity without evidence of radiological disease progression cannot be eligible for the study","ALL","18 Years",{"count":19,"type":20},108,"ESTIMATED","OBSERVATIONAL","The scope of GALILEO project (Genomic ALteratIons and cLonal EvOlution in ALK+ NSCLC) is to explore the feasibility of genomic longitudinal evaluation for ALK+ NSCLC patients in Italian routine practice and provide a detailed overview of resistance mechanisms and clinical outcomes according to current standard treatments.",[24,25,26],"ALK Gene Mutation","NSCLC Stage IV","ALK Sensitizing Mutation",[28,29],"ALK mutation","NSCLC","RECRUITING","2024-07-29",{"date":33,"type":34},"2024-07-31","ACTUAL",{"date":36,"type":34},"2021-07-12",{"date":38,"type":20},"2026-07-31",{"name":40,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",""]